Employing loss-of-function studies, we demonstrated that decreasing KIF2C expression inhibited cell proliferation, migration, and invasion in vitro and inhibited tumor growth in vivo, suggesting an oncogenic role of KIF2C during EC progression. The gene discussed is KIF2C; the disease is neoplasm.